Snapshot from Aug 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Promatix awarded Innovate UK grant for ADC
Business grant award

Promatix awarded Innovate UK grant for ADC

Analysis based on 7 articles · First reported Jul 28, 2026 · Last updated Aug 04, 2026

Sentiment
20
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The grant provides non-dilutive funding to Promatix, supporting its lead ADC programme and potentially enhancing its valuation ahead of a Series A financing. It also validates the company's platform, which may attract future partnerships and investment in the oncology ADC space.

Biotechnology Pharmaceuticals
Event Summary

Promatix Biosciences, a UK-based biotechnology company, announced on July 28, 2026, that it has been awarded a grant under the United Kingdom — Innovate UK Biomedical Catalyst 2025: Industry-led R&D small projects competition. The non-dilutive funding will support the advancement of Promatix's lead cis-bispecific antibody-drug conjugate (ADC), PBS293-exatecan, towards development candidate nomination. The award funds manufacturing scale-up, additional preclinical proof-of-concept studies in cell-line-derived and patient-derived xenograft models, and IND-enabling regulatory safety studies. The programme also expands the potential of the EGFR x EphA2 programme beyond colorectal cancer to oesophageal cancer and non-small cell lung cancer. The work will be conducted with UK-based contract research organisations including Abzena, Altor BioScience and Labcorp UK. Promatix's CEO and CSO expressed that the funding provides external validation and supports future pharma partnerships and a planned Series A financing.

Key Actions
100 United Kingdom — Innovate UK awarded grant Promatix Biosciences
60 Promatix Biosciences announced grant
Entities Involved
priv
Promatix Biosciences
Promatix is the grant recipient and central to the event. The funding supports its lead ADC programme and platform, potentially increasing its value and attractiveness to investors and partners.
Importance 100.0 Sentiment 70.0
govactor
United Kingdom — Innovate UK
United Kingdom — Innovate UK awarded the grant, providing non-dilutive funding to Promatix. This supports UK innovation and the biomedical sector, with no direct financial impact on United Kingdom — Innovate UK.
Importance 80.0 Sentiment 20.0
per
Roy Pettipher
Roy Pettipher is the Chief Scientific Officer and Co-Founder of Promatix, and his leadership is key to advancing the programme. The grant supports his work.
Importance 40.0 Sentiment 20.0
per
Michael Hunter
Michael Hunter is the CEO and Co-Founder of Promatix, and the grant supports his plans for partnerships and Series A financing.
Importance 40.0 Sentiment 20.0
cnt
United Kingdom
The United Kingdom is the location of Promatix and the grant provider, benefiting from innovation and economic growth in the biotech sector.
Importance 30.0 Sentiment 10.0
govactor
United Kingdom — UK Research and Innovation
United Kingdom — UK Research and Innovation is the parent body of United Kingdom — Innovate UK, indirectly involved through the grant programme. The award reflects its support for UK R&D.
Importance 30.0 Sentiment 10.0
priv
Abzena
Abzena is a contract research organisation that will conduct work for Promatix under the grant, potentially benefiting from the collaboration.
Importance 20.0 Sentiment 10.0
priv
Altor BioScience
Altor BioScience is a contract research organisation involved in the preclinical studies, potentially gaining revenue from the project.
Importance 20.0 Sentiment 10.0
stock
Labcorp
Labcorp UK is a contract research organisation that will support the programme, potentially benefiting from the collaboration.
Importance 20.0 Sentiment 10.0
Relationships
United Kingdom related ↔ United Kingdom — UK Research and Innovation
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.